Skip to main content
Livermore
Livermore
ZHEN

Barclays PLC

SEC CIK
0000312069
Latest filing
Aug 14, 2026

AKRO holding history

Akero Therapeutics, Inc. in every 13F filed by Barclays PLC, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

AKRO overviewAll 13F holders of AKROFull Q2 2026 holdings

Shares (Q4 2025)
0
Sold out in Q4 2025
Value
$0
% of portfolio
0.0%
Quarters held
19
Since Q1 2021
Holdings of AKRO by Barclays PLC, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q4 20250$00.0%−487,230−100.0%Sold outHolders
Q3 2025487,230$23.1M<0.1%−46,186−8.7%ReducedHolders
Q2 2025533,416$28.5M<0.1%+410,253+333.1%AddedHolders
Q1 2025123,163$4.99M<0.1%−9,674−7.3%ReducedHolders
Q4 2024132,837$3.70M<0.1%+5,169+4.0%AddedHolders
Q3 2024127,668$3.66M<0.1%+71,652+127.9%AddedHolders
Q2 202456,016$1.31M<0.1%−14,665−20.7%ReducedHolders
Q1 202470,681$1.79M<0.1%−175,593−71.3%ReducedHolders
Q4 2023246,274$5.75M<0.1%+114,828+87.4%AddedHolders
Q3 2023131,446$6.65M<0.1%−11,632−8.1%ReducedHolders
Q2 2023143,078$6.68M<0.1%+65,854+85.3%AddedHolders
Q1 202377,224$2.95M<0.1%−26,328−25.4%ReducedHolders
Q4 2022103,552$5.67M<0.1%+102,364+8,616.5%AddedHolders
Q3 20221,188$40.0K<0.1%−10,890−90.2%ReducedHolders
Q2 202212,078$114.0K<0.1%+4,468+58.7%AddedHolders
Q1 20227,610$107.0K<0.1%−27,820−78.5%ReducedHolders
Q4 202135,430$749.0K<0.1%+21,362+151.8%AddedHolders
Q3 202114,068$315.0K<0.1%+8,592+156.9%AddedHolders
Q2 20215,476$136.0K<0.1%−7,281−57.1%ReducedHolders
Q1 202112,757$369.0K<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.